JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

JNJ

225.83

+0.36%↑

UNH

362.86

-1.84%↓

TMO

464.87

-0.1%↓

ISRG

449.45

-0.24%↓

ABT

87.44

-0.74%↓

Home・Aandelen Lijst・Maravai LifeSciences Holdings Inc (Class A)

Search

Maravai LifeSciences Holdings Inc (Class A)

Open

SectorGezondheidszorg

3.72 0.81

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.7199999999999998

Max

3.75

Belangrijke statistieken
By Trading Economics
Inkomsten	-15M -40M
Verkoop	8.2M 50M
Winstmarge	-80.43
Werknemers	435
EBITDA	-19M -42M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+7.24% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-578M 543M
Vorige openingsprijs	2.91
Vorige sluitingsprijs	3.72

Nieuwssentiment

By Acuity

50%

50%

176 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

2.02 / 2.115 Steun & Weerstand

Maravai LifeSciences Holdings Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 mei 2026, 22:17 UTC

Winsten

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4 mei 2026, 23:47 UTC

Winsten

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4 mei 2026, 23:45 UTC

Winsten

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4 mei 2026, 23:40 UTC

Marktinformatie

Gold Steady Amid Likely Technical Recovery -- Market Talk

4 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

Regis: Jim Beyer To Be Chief Executive of Combined Company

4 mei 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4 mei 2026, 22:42 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4 mei 2026, 22:41 UTC

Acquisities, Fusies, Overnames

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Shareholders to Own About 51% of Combined Company

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Board Unanimously Endorsed, Supported Deal

4 mei 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Regis: Deal Unanimously Recommended by Vault Board

4 mei 2026, 22:39 UTC

Acquisities, Fusies, Overnames

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources to Acquire All Ordinary Shares in Vault

4 mei 2026, 22:38 UTC

Acquisities, Fusies, Overnames

Regis Resources, Vault Minerals Agree to Merger of Equals

4 mei 2026, 22:37 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4 mei 2026, 22:26 UTC

Winsten

Acquisities, Fusies, Overnames

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4 mei 2026, 22:02 UTC

Winsten

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4 mei 2026, 22:00 UTC

Marktinformatie

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4 mei 2026, 21:52 UTC

Winsten

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Some Sectors More Affected Than Others>WBC.AU

4 mei 2026, 21:50 UTC

Winsten

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4 mei 2026, 21:49 UTC

Winsten

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4 mei 2026, 21:44 UTC

Winsten

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4 mei 2026, 21:43 UTC

Winsten

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4 mei 2026, 21:41 UTC

Winsten

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4 mei 2026, 21:40 UTC

Winsten

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Peer Vergelijking

Prijswijziging

Maravai LifeSciences Holdings Inc (Class A) Prognose

Koersdoel

By TipRanks

7.24% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 4 USD 7.24%

Hoogste 5 USD

Laagste 3 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Maravai LifeSciences Holdings Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

6 ratings

3

Buy

3

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Maravai LifeSciences Holdings Inc (Class A) - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

2.02 / 2.115Steun & Weerstand

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

There are no events.

Sentiment

By Acuity

176 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Maravai LifeSciences Holdings Inc (Class A)

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Andere aandelen uit de sector

JNJ

Johnson and Johnson

225.83

UNH

UnitedHealth Group Inc

362.86

TMO

Thermo Fisher Scientific Inc

464.87

ISRG

Intuitive Surgical Inc

449.45

ABT

Abbott Laboratories

87.44

Live chat